Insider Trading & Ownership of James E. Flynn

Location
New York, NY
Summary
The estimated net worth of James E. Flynn is at least $2.25B dollars as of 24 Nov 2025. James E. Flynn is the Director, Director by Deputization, 10%+ Owner of Nuvalent, Inc. and owns shares of Nuvalent, Inc. (NUVL) stock worth about $1.64B. James E. Flynn is the 10%+ Owner of ARS Pharmaceuticals, Inc. and owns shares of ARS Pharmaceuticals, Inc. (SPRY) stock worth about $180M. James E. Flynn is the *Possible Member of 10% Group, 10%+ Owner of AdaptHealth Corp. and owns shares of AdaptHealth Corp. (AHCO) stock worth about $142M. James E. Flynn is the Director, * Director by Deputization, 10%+ Owner of Larimar Therapeutics, Inc. and owns shares of Larimar Therapeutics, Inc. (LRMR) stock worth about $99.1M. James E. Flynn is the * Possible Member of 10% Group, 10%+ Owner of Mirum Pharmaceuticals, Inc. and owns shares of Mirum Pharmaceuticals, Inc. (MIRM) stock worth about $91M. James E. Flynn is the Director, Director by Deputization, 10%+ Owner of CareMax, Inc. and owns shares of CareMax, Inc. stock worth about $54.7M. James E. Flynn is the Possible Members of 10% Group, 10%+ Owner of Bicara Therapeutics Inc. and owns shares of Bicara Therapeutics Inc. (BCAX) stock worth about $23.8M. James E. Flynn is the Director, Director by deputization of Acutus Medical, Inc. and owns shares of Acutus Medical, Inc. (AFIB) stock worth about $4.16M. James E. Flynn is the Possible Member of 10% Group, 10%+ Owner of PepGen Inc. and owns shares of PepGen Inc. (PEPG) stock worth about $3.97M. James E. Flynn is the *Possible Member of 10% Group, 10%+ Owner of Singular Genomics Systems, Inc. and owns shares of Singular Genomics Systems, Inc. stock worth about $3.89M. James E. Flynn is the Possible Members of 10% Group, 10%+ Owner of Fractyl Health, Inc. and owns shares of FRACTYL HEALTH, INC. (GUTS) stock worth about $2.42M. James E. Flynn is the Director, *Director by Deputization of BiomX Inc. and owns shares of BiomX Inc. (PHGE) stock worth about $2.32M. James E. Flynn is the Possible Member of 10% Group, 10%+ Owner of Xilio Therapeutics, Inc. and owns shares of Xilio Therapeutics, Inc. (XLO) stock worth about $1.9M. James E. Flynn is the Possible Members of 10% Group, 10%+ Owner of Oncology Institute, Inc. and owns shares of Oncology Institute, Inc. (TOI) stock worth about $448K.
Signature
/s/ Jonathan Isler, Attorney-in-Fact
All Insider Reports
All Insider Reports

Notify me when James E. Flynn files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of James E. Flynn

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
NUVL Nuvalent, Inc. Director, Director by Deputization, 10%+ Owner $1.64B -$70.9M -4.14% 24 Nov 2025
SPRY ARS Pharmaceuticals, Inc. 10%+ Owner $180M -$13.7M -7.04% 27 Jun 2025
AHCO AdaptHealth Corp. *Possible Member of 10% Group, 10%+ Owner $142M 08 Mar 2024
LRMR Larimar Therapeutics, Inc. Director, * Director by Deputization, 10%+ Owner $99.1M +$30M +43.4% 31 Jul 2025
MIRM Mirum Pharmaceuticals, Inc. * Possible Member of 10% Group, 10%+ Owner $91M 06 Jun 2022
CMAX CareMax, Inc. Director, Director by Deputization, 10%+ Owner $54.7M 17 Nov 2023
BCAX Bicara Therapeutics Inc. Possible Members of 10% Group, 10%+ Owner $23.8M 17 Sep 2024
AFIB Acutus Medical, Inc. Director, Director by deputization $4.16M 27 Jan 2025
PEPG PepGen Inc. Possible Member of 10% Group, 10%+ Owner $3.97M 10 May 2022
OMIC Singular Genomics Systems, Inc. *Possible Member of 10% Group, 10%+ Owner $3.89M 01 Jun 2021
GUTS FRACTYL HEALTH, INC. Possible Members of 10% Group, 10%+ Owner $2.42M 06 Feb 2024
PHGE BiomX Inc. Director, *Director by Deputization $2.32M 21 Apr 2025
XLO Xilio Therapeutics, Inc. Possible Member of 10% Group, 10%+ Owner $1.9M 26 Oct 2021
TOI, DFPH Oncology Institute, Inc. Possible Members of 10% Group, 10%+ Owner $448K 12 Nov 2021
FLAC Frazier Lifesciences Acquisition Corp Possible Member of 10% Group, 10%+ Owner 08 Nov 2022
ONCR Oncorus, Inc. Possible Member of 10% Group, 10%+ Owner 28 Dec 2022

Insider Transactions Reported by James E. Flynn:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.